ERBB2 and breast cancer: HER2-positive tumors have been initially described in breast cancer and more recently in GEC using immunohistochemistry (IHC), with further fluorescence in situ hybridization (FISH) or silver in situ hybridization (SISH) for those classified as uncertain to verify HER2 gene amplification (11).